PTC Therapeutics, Inc. (PTCT)

Market Cap	5.99B +66.5%
Revenue (ttm)	1.01B -42.8%
Net Income	-38.38M
EPS	-0.47
Shares Out	83.46M
PE Ratio	n/a
Forward PE	52.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	232,596
Open	71.58
Previous Close	71.97
Day's Range	70.85 - 71.88
52-Week Range	47.35 - 90.87
Beta	0.55
Analysts	Buy
Price Target	99.29 (+38.4%)
Earnings Date	Jul 30, 2026

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2013
• Employees: 991
• Stock Exchange: NASDAQ
• Ticker Symbol: PTCT
• Website: https://www.ptcbio.com

Analyst Summary

According to 14 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $99.29, which is an increase of 38.40% from the latest price.

Price Target

$99.29

(38.40% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 14, 2026

Data Sources Report a data error